Medogistin is used for Meniere’s disease / syndrome, accompanied by dizziness, nausea, hearing loss, tinnitus.
active substance: betahistine dihydrochloride;
1 tablet contains betahistine dihydrochloride 24 mg;
excipients: lactose monohydrate; corn starch; microcrystalline cellulose; citric acid anhydrous; povidone; crospovidone; hydrogenated vegetable oil.
It is a remedy for vestibular disorders. Affects the H1-, H3-histamine receptors of the labyrinth, the vestibular nuclei of the brain. Shows a pronounced H1-agonistic effect on the receptors of the vessels of the inner ear, promoting local vasodilation, significantly improving blood circulation in the stria vascularis. By acting on the H3 receptors of the neurons of the vestibular nuclei, it improves capillary permeability, increases the release of histamine, enhances microcirculation, increases the exchange of fluids at the level of the microvasculature, while normalizing the endolymph pressure in the cochlea and labyrinth. It also improves neuronal transmission by increasing the amount of serotonin in synapses. Inhibits the enzyme diamine oxidase, which inactivates histamine. The drug does not have sedative properties, does not affect systemic blood pressure indicators, does not provoke extrapyramidal disorders, therefore it can be used to treat elderly patients with parkinsonism.
Medogystin is used for Meniere’s disease / syndrome, accompanied by dizziness, nausea, hearing loss, tinnitus.
- with intolerance to the components of the drug;
- with pheochromocytoma (a hormonally active tumor that secretes catecholamines).
Medogystin is not recommended for use in children due to a lack of data on safety and efficacy.
Application during pregnancy and lactation
Due to the lack of information on the effect of the active substance (betahistine) on the development of the fetus, the appointment of Medogystin in the first trimester of pregnancy is unacceptable, and in the future it is possible only under strict medical supervision.
When prescribing this medication to a breastfeeding woman, she should refuse to breastfeed.
Method of administration and dosage
Medogystin is administered orally.
The dose prescribed by the doctor is taken 2-3 times a day during or after meals.
The course of therapy is from 2 weeks to 3 months, depending on the clinical effect. Optimal results are achieved with long-term use.
The standard dose is 8 mg 3 times a day. It is allowed to increase the dose to 16 mg three times a day or 24 mg twice a day in case of severe symptoms of the disease, ineffectiveness of treatment.
The maximum total dose is 48 mg / day.
The regression of symptoms can be observed only after 2-3 weeks of treatment. Optimal results are sometimes achieved after taking the drug for several months.
Symptoms: nausea, drowsiness, abdominal pain, seizures, heart disorders, pulmonary disorders.
If the dose is significantly exceeded, you should consult your doctor. If necessary, symptomatic, supportive treatment is carried out with monitoring of the functions of vital organs.
- Immune disorders: hypersensitivity, urticaria, angioedema, anaphylaxis.
- Neurological disorders: dizziness, headache.
- Gastrointestinal disorders: nausea, dyspepsia, vomiting, pain in the abdominal region, pain / cramps along the gastrointestinal tract, flatulence (bloating).
- Dermatological disorders: exanthema, itching.
Storage conditions and periods
Store Medogystin at temperatures from +15 to + 25 ° C for no more than three years from the date of production. It is forbidden to use the medicine after the expiration date (look at the package).